Rob Dillard

DocwireNews

<p>The oral androgen receptor Enzalutamide improves outcomes for men with metastatic hormone-sensitive prostate cancer (mHSPC), according to a study presented during the American Society of Clinical Oncology (ASCO) Annual Meeting and <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa1903835?query=featured_home">published</a> in <em>The New England Journal of Medicine.</em><p>Researchers of this open label, randomized, phase III trial arbitrarily assigned 1,125 men to receive either testosterone suppression plus either open enzalutamide or the standard nonsteroidal antiandrogen therapy. The average follow-up in this study was 34 months. Overall survival was established as the primary end point, while secondary end points, determined by the prostate-specific antigen (PSA) level, included progression-free survival, clinical-progression-free survival, as well as adverse events.</p><p>Results of the study showed that there were 102 deaths in the enzalutamide group and 143 deaths in the standard-care group (HR=0.67; 95% CI, 0.52 to 0.86; P=0.002). Kaplan&ndash;Meier estimates used in the study suggest overall survival at three years were 80% (based on 94 events) in the enzalutamide group juxtaposed to 72% (based on 130 events) in the standard-care group. Moreover, improved results with enzalutamide were also seen in PSA progression-free survival (174 and 333 events, respectively; HR=0.39; P&lt;0.001) and in clinical progression-free survival (167 and 320 events, respectively; HR=0.40; P&lt;0.001). However, treatment discontinuation due to adverse events was more prevalent in the enzalutamide group than in the standard-care group (33 events and 14 events, respectively). Furthermore, fatigue was more common in the enzalutamide group with seizures occurred in seven patients in the enzalutamide group (1%) compared to zero in the standard-care group.</p><blockquote class="twitter-tweet" data-width="500" data-dnt="true">
<p lang="en" dir="ltr">Enzalutamide improves survival for men with metastatic hormone-sensitive prostate cancer <a href="https://t.co/Zxo2OHL2Sf">https://t.co/Zxo2OHL2Sf</a> <a href="https://t.co/LEgMzpUlfP">pic.twitter.com/LEgMzpUlfP</a></p>
<p>&mdash; Bioengineer.org (@bioengineerorg) <a href="https://twitter.com/bioengineerorg/status/1135152515761262593?ref_src=twsrc%5Etfw">June 2, 2019</a></p>
</blockquote><p><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></p><h2><strong>An Alternative to Chemotherapy</strong></h2><p>&ldquo;These findings are truly practice-informing, adding an effective drug option in treating mHSPC,&rdquo; said study co-chair Sweeney who presented results during the ASCO plenary session. &ldquo;Adding enzalutamide to testosterone suppression in men with mHSPC can give much better cancer control and much longer survival. This is true both for patients with high burden of disease, with multiple bone metastases or liver metastases, as well as men with a lower burden of disease. The new treatment option is especially relevant for men who cannot tolerate chemotherapy and have a lower burden of disease.&rdquo;</p><p>&ldquo;The benefits of enzalutamide had already been established for prostate cancers that are no longer responding to hormonal therapy,&rdquo; said Ian D. Davis, MBBS, PhD, ANZUP chair and study co-chair. &ldquo;The actual result in patients starting hormonal therapy, noting patients had a 60% improvement in the time it takes to detect the cancer growing again along with a 33% increase chance of survival, was far higher than we expected.&rdquo;</p><blockquote class="twitter-tweet" data-width="500" data-dnt="true">
<p lang="en" dir="ltr">Enzalutamide improves survival for men with metastatic hormone-sensitive prostate cancer <a href="https://t.co/yMArURr7di">https://t.co/yMArURr7di</a></p>
<p>&mdash; Science Codex (@sciencecodex) <a href="https://twitter.com/sciencecodex/status/1135228720954822656?ref_src=twsrc%5Etfw">June 2, 2019</a></p>
</blockquote><p><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></p><blockquote class="twitter-tweet" data-width="500" data-dnt="true">
<p lang="en" dir="ltr"><a href="https://twitter.com/hashtag/Enzalutamide?src=hash&amp;ref_src=twsrc%5Etfw">#Enzalutamide</a> improves survival for men with metastatic hormone-sensitive prostate <a href="https://twitter.com/hashtag/cancer?src=hash&amp;ref_src=twsrc%5Etfw">#cancer</a> <a href="https://twitter.com/DanaFarber?ref_src=twsrc%5Etfw">@danafarber</a> <a href="https://twitter.com/NEJM?ref_src=twsrc%5Etfw">@nejm</a> <a href="https://t.co/7hkMdT3yhF">https://t.co/7hkMdT3yhF</a></p>
<p>&mdash; Medical Xpress (@medical_xpress) <a href="https://twitter.com/medical_xpress/status/1135439325674508289?ref_src=twsrc%5Etfw">June 3, 2019</a></p>
</blockquote><p><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></p></p>


Connie Rhee, MD

Joel M. Topf, MD, FACP

CKD Management and Cognition

NKF Spring Clinical Meetings 2025

Bradley Marder, MD

Gout Studies: Transplant Waitlisting and Bone Erosion

Jayme Locke, MD, MPH

The Promise of Xenotransplantation

Latest News

Enzalutamide Can Improve Outcomes for Men with Metastatic Prostate Cancer

Oncology

The oral androgen receptor Enzalutamide improves outcomes for men with metastatic hormone-sensitive prostate cancer (mHSPC), according to a study presented during the American ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe